Proline

Proline

SCHEMBL2173873

O=C(O)[C@@H]1CCCN1.[Cu+].[I-]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NOS2 P35228 2/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
DPP4 P27487 4/20 0.46
DPP8 Q6V1X1 2/20 0.46
DPP9 Q86TI2 2/20 0.46
FAP Q12884 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
LMNA P02545 3/20 0.40
CYP2D6 P10635 2/20 0.40
TSHR P16473 2/20 0.40
SLC6A1 P30531 2/20 0.40
ALOX15 P16050 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
SLC6A11 P48066 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Proline SCHEMBL31370901 0.98
Proline SCHEMBL6894672 0.95 BLM (0.52) BLMMEN1KMT2ANOS2NOS3
Proline SCHEMBL462226 0.95 BLM (0.52) BLMMEN1KMT2ANOS2NOS3
Proline SCHEMBL18875607 0.95
Proline SCHEMBL718906 0.95 BLM (0.52) BLMMEN1KMT2ANOS2NOS3
Proline SCHEMBL10141181 0.95
Proline SCHEMBL10141185 0.95
Proline SCHEMBL13248912 0.95
D-Proline SCHEMBL21462052 0.95 BLM (0.52) BLMMEN1KMT2ANOS2NOS3
Proline SCHEMBL2939 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111410666-A Process for preparing sulfonamide compound 苏州亚盛药业有限公司 2020-07-14 CN claimed
US-11370807-B2 Process for preparing sulfonamide compounds ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2022-06-28 US disclosed
US-20220009952-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2022-01-13 US disclosed
EP-3820878-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2021-05-19 EP disclosed
CN-111410666-B Process for preparing sulfonamide compound 苏州亚盛药业有限公司 2021-02-19 CN disclosed
CN-111410666-A Process for preparing sulfonamide compound 苏州亚盛药业有限公司 2020-07-14 CN disclosed
WO-2020140956-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-09 WO disclosed
US-9458155-B2 Pyrido[4,3-b]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC (US) 2016-10-04 US disclosed
US-20150051218-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. 2015-02-19 US disclosed
US-8907097-B2 Pyrido[4,3-b]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC. (US) 2014-12-09 US disclosed
US-8906925-B2 Pyrido[4,3-B]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC. (US) 2014-12-09 US disclosed
US-20130190322-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 US disclosed
EP-2346332-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES Medivation Technologies, Inc. (US) 2011-07-27 EP disclosed
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. 2010-08-26 US disclosed
WO-2010051501-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051218-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES HTR3B, HTR3D, HTR3A BLM 4700/4885MEN1 4283/4885KMT2A 366/4885
US-11370807-B2 Process for preparing sulfonamide compounds BCL2, BCL3, BAX BLM 4584/4885MEN1 4035/4885KMT2A 480/4885
US-20130190322-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES HTR3B, HTR3D, HTR3A BLM 4700/4885MEN1 4283/4885KMT2A 366/4885
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES HTR3B, HTR3D, HTR3A BLM 4700/4885MEN1 4283/4885KMT2A 366/4885
US-20220009952-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS BCL2, BCL3, BAX BLM 4584/4885MEN1 4035/4885KMT2A 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.